BPC-157 vs TB-500: different mechanisms, often paired
BPC-157 is a 15-residue peptide derived from a gastric protein, studied for growth-factor and angiogenic signalling in tendon, gut and vascular repair models. TB-500 is a fragment of thymosin beta-4 that binds actin, studied for cell migration and wound healing. They are paired because the mechanisms are different, not because either replaces the other.
| BPC-157 | TB-500 | |
|---|---|---|
| Origin | Gastric juice protein sequence | Thymosin beta-4 fragment |
| Length | 15 amino acids | Fragment of a 43-residue protein |
| Proposed mechanism | Growth-factor receptor expression, NO signalling, angiogenesis | Actin sequestration, cell migration, angiogenesis |
| Strongest model literature | Tendon, gut lining, vascular | Dermal wound, corneal, cardiac |
| Main research group | Sikiric, Zagreb | Goldstein, Kleinman and others |
| Human trials | None completed | None for the fragment |
| Current lot purity | 99.73% (BP5-0803) | 99.68% (TB10-0803) |
| Vial | 5 mg, $48 | 5 mg, $52 |
| Together | Repair pair bundle, $88, or the 1:1 blend, $85 |
Which has the larger literature?
BPC-157, by volume: three decades of rodent studies, mostly from one group. TB-500's parent protein thymosin beta-4 has a broad and independent literature, but work on the isolated fragment is smaller. Neither has completed human trials, which is the honest state of the field.
When would you use only one?
Use BPC-157 alone for gut-lining and tendon models where the growth-factor mechanism is the question. Use TB-500 alone for migration assays and dermal wound models where actin dynamics is the readout. A single-peptide arm is also the control every combination protocol needs.
Blend or bundle?
The blend fixes the ratio at 1:1 in one vial and gives one certificate reporting both. The bundle ships two vials with two certificates and lets you set the ratio. For a first protocol the bundle is the flexible choice; the blend suits multi-site work where preparation variance matters more.
What do the current certificates show?
Pharmacology decides which compound answers the question; the certificate decides what is actually in the vial. These are the current lots for each, read from the certificate library:
| Compound | Lot | Identity | Purity | Content | Issued |
|---|---|---|---|---|---|
| BPC-157 | BP5-0803 | LC-MS/MS | 99.73% | 5.33 mg vs 5 mg label | Aug 17, 2026 |
| TB-500 | TB10-0803 | LC-MS/MS | 99.68% | 10.23 mg vs 10 mg label | Aug 17, 2026 |
Purity on both lines is area percent by RP-HPLC at 214 nm, which the area-percent post explains is a ratio of peak areas and not a weight, so the two figures are comparable only because the method is the same. Content is the measured mass against the label, and the lot-to-lot post is the case for using it rather than the label in any calculation. All 114 certificates read together are in the certificate dataset.
Common questions
Can BPC-157 and TB-500 be used together?
They are frequently studied as a pair, and this catalogue sells both separately and as a co-lyophilized blend. Separate vials keep the ratio adjustable; the blend fixes it.
Which is the larger molecule?
BPC-157, at 15 residues and 1419.5 g/mol. TB-500 is the 7-residue actin-binding fragment at 889.0 g/mol.
Where to go next
For laboratory research use only. Clinical trial results are cited as context and do not describe use of the material sold here.